Inotropic and diuretic effects of GLP-1 and GLP-1 agonists
US7442680B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 5, 2003 |
| Grant date | Oct 28, 2008 |
| Priority date | — |
| Expiry date | Dec 22, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P13/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.